Reclast (Zoledronic Acid) vs Evenity (Romosozumab): Head-to-Head Efficacy

What These Two Drugs Actually Do Differently

Zoledronic acid and romosozumab attack osteoporosis through completely different biological pathways. That distinction drives every clinical decision about which to use first.

Zoledronic acid is a nitrogen-containing bisphosphonate. It binds to hydroxyapatite in bone mineral and is taken up by osteoclasts, where it inhibits farnesyl pyrophosphate synthase, triggering osteoclast apoptosis [1]. The result is a sustained reduction in bone resorption that persists for 12 months from a single 15-minute infusion.

Romosozumab is a monoclonal antibody that binds sclerostin, a protein secreted by osteocytes that normally suppresses both bone formation and increases bone resorption [2]. Blocking sclerostin simultaneously stimulates osteoblast activity and reduces osteoclast recruitment. This dual action is why romosozumab produces BMD gains roughly two to three times larger than antiresorptive drugs in the same timeframe.

Why Mechanism Shapes the Clinical Decision

The mechanism difference has a direct clinical implication. Romosozumab's anabolic effect is transient. After 12 months, sclerostin levels rebound and the formation signal fades, leaving behind denser bone that will erode unless an antiresorptive drug is started immediately [3]. Zoledronic acid, by contrast, has residual activity that persists in bone tissue for years after infusions stop, which supports the practice of a drug holiday after 3 to 6 years of therapy [4].

Choosing between them is not simply a question of which drug is stronger. The question is which drug fits the patient's fracture risk timeline, cardiovascular history, and available follow-on therapy.

HORIZON-PFT: The Evidence Base for Zoledronic Acid

Trial Design and Population

HORIZON-PFT (Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Key Fracture Trial) enrolled 7,765 postmenopausal women with osteoporosis and randomized them 1:1 to zoledronic acid 5 mg IV annually or placebo for 36 months [1]. Mean age was 73 years. Mean lumbar spine T-score at baseline was approximately -2.8.

Fracture Outcomes

Published in the New England Journal of Medicine in 2007, HORIZON-PFT reported a 70% reduction in morphometric vertebral fractures (3.3% zoledronic acid vs 10.9% placebo; P<0.001) [1]. Hip fracture risk fell by 41% (1.4% vs 2.5%; P=0.002). Non-vertebral fracture risk dropped 25% (P<0.001).

The 2012 extension data showed that women who received three years of zoledronic acid and then stopped maintained fracture protection for an additional three years compared with those switched to placebo, supporting a drug holiday strategy [4].

BMD Gains

Lumbar spine BMD increased by 6.7% from baseline at 36 months in HORIZON-PFT [1]. Total hip BMD rose 6.0%. These are meaningful gains for an antiresorptive agent, though they are lower than the anabolic gains seen with romosozumab in ARCH.

Acute-Phase Reaction and Other Safety Signals

Approximately 32% of patients receiving their first zoledronic acid infusion experienced an acute-phase reaction: fever, myalgia, and flu-like symptoms lasting 24 to 72 hours [1]. Pre-hydration and acetaminophen reduce severity. Atrial fibrillation was numerically higher in the zoledronic acid arm (1.3% vs 0.5%), though adjudicated analyses and subsequent meta-analyses have not established a causal link [5]. Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) remain rare risks associated with long-term bisphosphonate use [6].

ARCH: The Evidence Base for Romosozumab

Trial Design and Population

ARCH (Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk) enrolled 4,093 postmenopausal women at high fracture risk and randomized them to romosozumab 210 mg SC monthly for 12 months followed by alendronate 70 mg weekly, versus alendronate alone for 24 months [7]. Participants needed either a prior fracture or very low T-score to qualify, making this a higher-risk cohort than HORIZON-PFT.

Fracture Outcomes at 24 Months

At 24 months (12 months romosozumab then 12 months alendronate vs 24 months alendronate), the romosozumab-transition group had 48% fewer new vertebral fractures (6.2% vs 11.9%; P<0.001) [7]. Clinical fracture risk fell by 27% (P<0.001). Hip fracture risk was reduced by 35% (2.0% vs 3.2%; P=0.04).

These numbers capture the combined effect of the romosozumab anabolic phase and the subsequent alendronate consolidation. The fracture reduction attributable to romosozumab alone is best read from the 12-month interim data, where the vertebral fracture rate was already diverging significantly from the control arm [7].

BMD Gains

At 12 months, romosozumab produced a 13.7% increase in lumbar spine BMD and a 6.2% increase in total hip BMD [7]. These exceeded the BMD gains produced by alendronate alone in the same trial by a factor of roughly 2.5 for the spine.

Cardiovascular Safety Signal

The ARCH trial reported a higher rate of serious cardiovascular events (adjudicated MACE: myocardial infarction, stroke, or cardiovascular death) in the romosozumab arm: 2.5% vs 1.9% with alendronate (P=0.07 for the primary cardiovascular composite) [7]. The FDA reviewed this signal alongside data from the FRAME trial and concluded the risk was real enough to require a boxed warning on the Evenity label [8]. Romosozumab is contraindicated in patients who have had a myocardial infarction or stroke within the preceding year.

Side-by-Side Efficacy: Reading Across Trials

No randomized, double-blind, head-to-head trial has directly compared romosozumab with zoledronic acid. All comparative statements below are cross-trial inferences, not direct experimental results.

Vertebral Fracture Reduction

| Metric | Zoledronic Acid (HORIZON-PFT) | Romosozumab then Alendronate (ARCH) | |---|---|---| | Vertebral fracture RRR | 70% vs placebo | 48% vs alendronate alone | | Hip fracture RRR | 41% vs placebo | 35% vs alendronate | | Non-vertebral fracture RRR | 25% vs placebo | 19% vs alendronate | | Trial duration (active drug) | 36 months | 12 months romosozumab | | Comparator | Placebo | Active (alendronate) |

Comparing 70% against 48% is misleading without acknowledging the comparator difference. A 48% reduction versus an active bisphosphonate is arguably a stronger signal than a 70% reduction versus placebo, because placebo arms inflate relative risk reductions. Both numbers represent clinically meaningful fracture protection.

BMD Changes at 12 Months

Romosozumab produces roughly double the lumbar spine BMD gain of zoledronic acid in the first 12 months of treatment [1, 7]. For patients with a T-score below -3.5 or with a recent fragility fracture, that rapid BMD gain may reduce re-fracture risk faster than antiresorptive monotherapy. This is one reason the 2020 AACE/ACE guidelines recommend anabolic-first sequencing for very high-risk patients [9].

Speed of Fracture Protection

Zoledronic acid begins suppressing bone turnover markers within 24 hours of infusion, with significant fracture protection demonstrated by the 12-month mark in HORIZON-PFT [1]. Romosozumab's fracture benefit in ARCH was also measurable by 12 months, though the trial was designed around a 24-month primary endpoint [7]. Neither drug has been shown to prevent fractures faster than the other in a direct comparison.

Cardiovascular Risk: The Critical Safety Difference

This is where the two drugs diverge most sharply. Zoledronic acid has no FDA boxed warning for cardiovascular events. Romosozumab carries a black box warning stating: "Romosozumab-aqqg may increase the risk of myocardial infarction, stroke, and cardiovascular death. Romosozumab-aqqg should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year" [8].

The HealthRX clinical team uses the following cardiovascular pre-screening framework before initiating romosozumab:

1. Review the preceding 12 months for any MI, stroke, or TIA.
2. Calculate 10-year ASCVD risk using the Pooled Cohort Equations.
3. If ASCVD risk exceeds 20% or any qualifying cardiac event occurred within 12 months, prescribe zoledronic acid as the primary anabolic-sequencing anchor instead.
4. Confirm no severe renal impairment (eGFR <35 mL/min/1.73m2 is a contraindication to zoledronic acid; romosozumab has no renal dose adjustment requirement for moderate impairment but has limited data in severe CKD).
5. Obtain baseline dental evaluation for both drugs given shared ONJ risk [6].

The absolute risk difference for MACE in ARCH was 0.6 percentage points [7]. That is a small absolute number, but clinicians and patients weigh it differently depending on existing cardiovascular burden.

Renal Considerations: When Kidneys Change the Answer

Zoledronic acid requires dose adjustment and is contraindicated when creatinine clearance falls below 35 mL/min [10]. This rules it out for a meaningful proportion of older osteoporotic women who have concurrent CKD stage 3b or worse. The FDA label for Reclast specifies that it should not be used in patients with CrCl <35 mL/min [10].

Romosozumab's prescribing information does not list a renal dose adjustment for mild to moderate CKD, though the ARCH trial excluded patients with CrCl <30 mL/min, so data in severe CKD remain limited [8]. For patients with CKD stage 3b to 4 and no cardiovascular contraindications, romosozumab may be the more accessible of the two agents, though specialist nephrology input is appropriate before initiating either drug in advanced CKD.

Oral bisphosphonates (alendronate, risedronate) face the same renal restrictions as zoledronic acid and are generally avoided below CrCl 30 to 35 mL/min [11].

Dosing, Administration, and Adherence

Zoledronic Acid Dosing

The FDA-approved dose for osteoporosis treatment is 5 mg IV over no less than 15 minutes, once per year [10]. For Paget's disease, a single 5 mg dose is used. For osteoporosis prevention in postmenopausal women, 5 mg every two years is an approved option. Patients must be adequately hydrated before infusion. Creatinine and electrolytes should be checked before each annual infusion.

Adherence is near-perfect for the infusion period because the drug is administered in a clinical setting. Patients cannot miss a dose in the way they might forget a daily or weekly pill. This is a practical advantage over oral bisphosphonates [12].

Romosozumab Dosing

Romosozumab is given as two subcutaneous injections of 105 mg each (total 210 mg) once monthly for 12 months, administered by a healthcare provider or trained patient [8]. After 12 months, treatment must be transitioned to an antiresorptive drug. Continuing romosozumab beyond 12 months provides no additional benefit and is not approved.

Monthly clinic visits or injection training add a logistical burden that the annual zoledronic acid infusion does not. For patients with limited mobility or transportation challenges, this monthly visit schedule can affect completion rates.

Sequencing Strategies: Which Drug Goes First?

Antiresorptive First, Then Anabolic

Historically, patients received bisphosphonates first and anabolic agents second. Evidence now shows this sequence is suboptimal for very high-risk patients. Prior bisphosphonate use blunts the anabolic response to teriparatide, and a similar attenuation may occur with romosozumab, though the data are less definitive [13].

Anabolic First, Then Antiresorptive (Preferred for Very High Risk)

The AACE/ACE 2020 osteoporosis guidelines recommend that patients at very high fracture risk (T-score <-3.0, prior hip or vertebral fracture, or very high FRAX score) begin therapy with an anabolic agent followed by an antiresorptive [9]. The 2022 Endocrine Society guidelines echo this recommendation, citing the ARCH data as primary evidence [14].

After 12 months of romosozumab, zoledronic acid is the preferred consolidation agent in most guidelines. The transition prevents the rapid BMD loss that occurs when romosozumab is discontinued without follow-on therapy. One-year post-romosozumab BMD declines of 5 to 10% at the spine have been reported when no antiresorptive is started [3].

Zoledronic Acid as Monotherapy

For patients at high (but not very high) fracture risk, without a prior fracture and with a T-score between -2.5 and -3.0, zoledronic acid as primary monotherapy remains appropriate and cost-effective. Seventy percent vertebral fracture reduction with a single annual infusion is a compelling risk-benefit profile for this group [1].

Cost and Access

Generic zoledronic acid 5 mg costs approximately $30 to $60 per infusion at most infusion centers, plus the cost of the infusion visit [15]. Annual cost of therapy is typically under $300 for the drug itself.

Romosozumab (Evenity) listed at approximately $1,800 per monthly dose as of 2024, totaling roughly $21,600 for a complete 12-month course before insurance [15]. Most commercial plans and Medicare Part B cover romosozumab for patients with documented severe osteoporosis and prior fracture, but prior authorization requirements are common. Access barriers are real and affect clinical decision-making for many patients.

Practical Patient Selection

Three patient profiles illustrate how these data translate into clinical decisions.

Profile 1: 68-year-old woman, T-score -2.8, no prior fracture, no cardiovascular disease, normal renal function. Zoledronic acid is appropriate as first-line treatment. Annual infusion, 70% vertebral fracture protection, generic cost.

Profile 2: 74-year-old woman, T-score -3.5, recent vertebral compression fracture, no cardiovascular disease, eGFR 55. Very high fracture risk. Romosozumab for 12 months followed by annual zoledronic acid fits AACE and Endocrine Society guidance. Rapid BMD gain addresses the acute re-fracture risk window.

Profile 3: 71-year-old woman, T-score -3.0, prior stroke 8 months ago, eGFR 30. Romosozumab is contraindicated (recent stroke). Zoledronic acid is contraindicated (CrCl <35). This patient may require denosumab or teriparatide, and nephrology consultation is appropriate before any agent is started.

Switching Between Zoledronic Acid and Romosozumab

From Zoledronic Acid to Romosozumab

Patients who fracture on bisphosphonate therapy or who have persistently low T-scores despite adequate zoledronic acid adherence are candidates for escalation to romosozumab. The residual antiresorptive effect of prior zoledronic acid may modestly attenuate romosozumab's formation signal, though clinical fracture data supporting this concern are limited [13]. Current guidelines do not consider prior bisphosphonate use a contraindication to romosozumab initiation.

Clinicians should check cardiovascular history and perform a dental evaluation before making this switch. A minimum 12-month interval after the last zoledronic acid infusion is not required by labeling, but the transition typically follows a standard monitoring visit.

From Romosozumab to Zoledronic Acid

This is the most evidence-supported sequencing direction. After 12 months of romosozumab, zoledronic acid 5 mg IV should be given within one to three months of the final romosozumab injection to consolidate the BMD gains achieved during the anabolic phase [3, 7]. Delay beyond three to four months risks significant bone loss. The ARCH trial itself followed romosozumab with alendronate and demonstrated durable fracture protection through 24 months [7].

Switching from romosozumab to zoledronic acid does not require a washout period. The two drugs work through complementary mechanisms and there is no pharmacological reason to delay the antiresorptive transition.

Monitoring During Therapy

Bone Turnover Markers

Procollagen type I N-terminal propeptide (P1NP) reflects bone formation and rises sharply within one month of romosozumab initiation, then declines back to baseline by month 9 to 12 [7]. C-terminal telopeptide (CTX) reflects bone resorption and initially falls with romosozumab, then rises at the end of the 12-month course. Tracking both markers helps confirm biological response.

With zoledronic acid, CTX falls by 50 to 70% within three months of infusion and remains suppressed for 9 to 12 months [1]. P1NP falls proportionally. An inadequate CTX suppression at three months may indicate poor drug bioavailability or non-response.

DXA Timing

Repeat DXA is recommended at 24 months for patients on zoledronic acid and at 12 to 24 months after completing romosozumab, depending on baseline fracture risk and the antiresorptive agent used in the consolidation phase [9, 14]. Annual DXA for every patient on either drug is not warranted by guidelines and generates unnecessary radiation exposure and cost.